You searched for "regulation"

944 results found

Men with a susceptibility to prostate cancer: implications of ethnicity in PCa risk-prediction and diagnosis

The diagnostic and therapeutic landscapes of prostate cancer (PCa) have advanced at great pace in the past decade. However, disparities in access to care, clinical outcomes and representation in therapeutic, interventional and genomic studies continue to exist between Afro-Caribbean (AC)...

Opening doors to difficult conversations: Communication tips from urology Clinical Nurse Specialists

Effective communication lies at the heart of specialist urological cancer care. For clinical nurse specialists and urology nurses, conversations often extend far beyond diagnosis and treatment, encompassing some of the most sensitive and life-changing discussions patients may ever face. Whether...

The postcode lottery costing men with prostate cancer years of life

Nearly a third of men miss out on lifesaving treatments for prostate cancer – raising to more than half in worst-hit areas Prostate cancer can be cured if found early, but 31% of men diagnosed with aggressive but curable prostate...

Results from the REDUCE study

Subjects in this paper were part of the Reduction by Dutasteride of PCa Events (REDUCE) study, a clinical trial enrolling men who had undergone a single negative prostate biopsy within six months of enrollment and subjecting them to a repeat...

Near-infrared fluorescence in robotic surgery

This is a systematic review and critical analysis of the current evidence on the applications of near-infrared fluorescence (NIRF) in robotic urologic surgery. It uses indocyanine green (ICG), a sterile water-soluble dye which has been tested in various fields. In...

Comparison of PCNL under spinal versus general anaesthesia

There are several advantages of performing percutaneous nephrolithotomy (PCNL) under spinal anaesthesia including lower cost, reduced adverse effects and less tracheal tube displacement. Another advantage is that the patient remains awake throughout making positioning easier and reducing the risk of...

A phase II dose-ranging study of mirabegron in patients with OAB

This was a multinational, multicentre, randomised, double–blind, double-dummy, parallel group placebo- and active- controlled phase II study. The study enrolled 1108 men and women aged 18 and over. The criteria were: patients must have had overactive blader (OAB) symptoms for...

Prostate Cancer UK warns of over 8,600 ‘missing men’ as referrals drop by 52,000

The Covid-19 pandemic has led to around 52,000 (28%) fewer urgent prostate cancer referrals in England alone, according to statistics shared by Prostate Cancer UK. It’s estimated that more than 8,600 fewer men started treatment for...

Inguino-scrotal sarcomas

A sarcoma is a malignant tumour that originates from mesenchymal cells such as adipose tissue, bone, cartilage and smooth muscle. Although these tumours histologically do not originate from the urogenital tract, urologists are often involved in their diagnosis and management...

Prostate Scotland’s COMPASS Impact Report highlights how men in Scotland are benefiting from prostate cancer support services

Prostate Scotland has published its COMPASS Impact Report 2020-2024, providing a detailed account of how its support services are improving outcomes for men living with prostate cancer across Scotland. Developed to complement care provided by clinical teams, COMPASS helps men...

Prostatic urethral lift provides good alternative to TURP for men with LUTS

Lower urinary tract symptoms (LUTS) due to prostatic enlargement resulting in bladder outflow obstruction are common. Transurethral resection of the prostate (TURP) remains the gold standard in operative management, however it is not without its risks. In this multicentre European...

FRCS – the long way round

In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). This month I am joined by my friend and fellow member of the...